Natixis Advisors LLC Acquires 5,564 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Natixis Advisors LLC lifted its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 20.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 33,246 shares of the medical research company’s stock after acquiring an additional 5,564 shares during the quarter. Natixis Advisors LLC owned approximately 0.12% of Bio-Rad Laboratories worth $9,080,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Van ECK Associates Corp bought a new position in Bio-Rad Laboratories during the second quarter worth $180,040,000. Pine Valley Investments Ltd Liability Co acquired a new stake in shares of Bio-Rad Laboratories during the 2nd quarter worth about $234,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in shares of Bio-Rad Laboratories by 84.5% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,736 shares of the medical research company’s stock worth $474,000 after buying an additional 795 shares during the period. Crossmark Global Holdings Inc. grew its stake in Bio-Rad Laboratories by 5.6% in the 2nd quarter. Crossmark Global Holdings Inc. now owns 1,822 shares of the medical research company’s stock valued at $498,000 after buying an additional 97 shares during the last quarter. Finally, Innealta Capital LLC bought a new position in Bio-Rad Laboratories in the 2nd quarter valued at about $102,000. 65.24% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BIO has been the topic of several research reports. Jefferies Financial Group reaffirmed a “hold” rating and issued a $315.00 target price (down previously from $440.00) on shares of Bio-Rad Laboratories in a research report on Monday, June 3rd. Royal Bank of Canada reiterated an “outperform” rating and set a $401.00 price objective on shares of Bio-Rad Laboratories in a research report on Friday, August 16th. StockNews.com cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 price target on the stock. Finally, Citigroup lifted their price objective on shares of Bio-Rad Laboratories from $300.00 to $350.00 and gave the stock a “neutral” rating in a research note on Friday, August 2nd. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $358.20.

Bio-Rad Laboratories Stock Performance

NYSE BIO opened at $333.05 on Friday. The firm’s 50 day simple moving average is $312.33 and its 200 day simple moving average is $308.31. The firm has a market capitalization of $9.50 billion, a price-to-earnings ratio of -32.15 and a beta of 0.93. The company has a current ratio of 6.28, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 1 year low of $261.59 and a 1 year high of $384.37.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Thursday, August 1st. The medical research company reported $3.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.12 by $0.99. Bio-Rad Laboratories had a positive return on equity of 3.77% and a negative net margin of 51.73%. The company had revenue of $638.50 million for the quarter, compared to analyst estimates of $645.79 million. During the same quarter last year, the company posted $3.00 EPS. The company’s revenue for the quarter was down 6.3% compared to the same quarter last year. As a group, research analysts expect that Bio-Rad Laboratories, Inc. will post 10.31 earnings per share for the current fiscal year.

Insider Buying and Selling at Bio-Rad Laboratories

In other news, EVP James Barry sold 623 shares of the stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total value of $205,895.27. Following the completion of the transaction, the executive vice president now owns 147 shares of the company’s stock, valued at $48,582.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Bio-Rad Laboratories news, EVP James Barry sold 623 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total transaction of $205,895.27. Following the sale, the executive vice president now owns 147 shares of the company’s stock, valued at $48,582.03. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Michael Crowley sold 369 shares of the stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $281.91, for a total value of $104,024.79. Following the completion of the transaction, the executive vice president now owns 6,573 shares of the company’s stock, valued at $1,852,994.43. The disclosure for this sale can be found here. Company insiders own 17.06% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.